Tumour shrinkage, clearance in advanced mesothelioma patients treated with BZDS1901 support exploration of higher dosing, further clinical development

• • All five advanced mesothelioma patients in extension Cohort 1 of the investigator-initiated trial of BZDS1901 have passed at least two months of follow-up.

  • 14 mesothelioma patients now treated: all had either previously not responded to, or relapsed after, chemotherapy or immunotherapy

  • Five of the ten patients receiving the highest doses of BZDS1901 are seeing tumour shrinkage of more than 30% (50% Overall Response Rate)

  • Tumours that were 5cm in size before BZDS1901 are now undetectable in two out of ten of these patients (20%, achieving criteria for a Complete Response) – highly unusual in patients who have already failed prior therapy

  • Response rates are almost double those seen with current treatments

  • Over a quarter of all patients have shown on-going tumour shrinkage, providing evidence of CAR-T persistence

  • Updated safety protocols have allowed higher doses to be given with manageable toxicities

  • These positive clinical results continue to support exploration of higher dosing and future studies

  AdAlta CEO and Managing Director, Tim Oldham said:

“These new clinical results reinforce our confidence that BZDS1901 can deliver much needed new hope for advanced mesothelioma patients and we look forward to ensuring Australian patients are the first outside China to gain access to this ground breaking therapy.”